

Preemptive Dose Adjustment Effect on the Quality of Anticoagulation Management in Warfarin Patients With Drug Interactions: A Retrospective Cohort Study

Amr Mohamed Fahmi, MClIn Pharm, BCCP¹,
Adham Mohamed, PharmD¹, Hazem Elewa, RPh, PhD, BCPS² ,
and Mohamed Omar Saad, PharmD, BCPS, BCCCP¹

Clinical and Applied
Thrombosis/Hemostasis
Volume 25: 1-6
© The Author(s) 2019
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/1076029619872554
journals.sagepub.com/home/cat



Abstract

One strategy to manage patients on warfarin starting an interacting drug is to increase the frequency of monitoring. Another strategy is to adjust warfarin dose around the time patient is started on an interacting medication, which is known as “preemptive warfarin dose adjustment.” The main objective of this study is to compare preemptive to nonpreemptive strategy and their impact on the quality of anticoagulation management. This is a retrospective cohort study performed at the pharmacist-managed anticoagulation clinic in a tertiary hospital in the State of Qatar. Over a 4-year period, 340 patients were evaluated, and 58 warfarin–drug interaction encounters were identified. Mean age of the patients was (57.7 ± 13.7), and 50% of them were females. Preemptive dose adjustment was used in 17 (29.3%) cases. Incidence of out-of-target international normalized ratio (INR) was statistically lower in the preemptive arm compared to the control group (41.2% [7/17] vs 69.2% [27/39], $P = .048$). Incidence of extreme out-of-target INR was numerically lower in the preemptive arm compared to the control but did not reach statistical significance (11.8% [2/17] vs 29.3% [12/41], $P = .139$). Change in frequency of INR monitoring was not different between the 2 groups. However, overall frequency of INR monitoring after onset/discontinuation of interacting medication increased compared to baseline (7 [9] vs 21 [16] days, $P < .001$). Preemptive strategy was shown in our study to decrease incidence of the out-of-target INR visits, although patients remained in need for close monitoring.

Keywords

warfarin, preemptive dosing, drug interactions, INR monitoring

Date received: 12 June 2019; revised: 20 July 2019; accepted: 05 August 2019.

Introduction

Warfarin is the mainstay oral anticoagulant medication and one of the most widely prescribed medications all over the world.¹ Because of its narrow therapeutic index and numerous drug and food interactions, close and consistent monitoring of anticoagulation is mandated to ensure optimal outcomes and minimize the risks associated with inappropriate management. International normalized ratio (INR) is a reliable surrogate marker that has been used for decades as an indicator for warfarin therapeutic effect and its interaction with food and drugs.² Drugs interacting with warfarin can have different mechanisms

including direct pharmacokinetic effect (induction or inhibition) on the Cytochrome P450 (CYP450) isoenzymes that are involved in the warfarin metabolism; altered absorption or

¹ Al Wakra Hospital, Hamad Medical Corporation, Al Wakra, Qatar

² Clinical Pharmacy and Practice Section, College of Pharmacy, Qatar University, Doha, Qatar

Corresponding Author:

Hazem Elewa, Clinical Pharmacy and Practice Section, College of Pharmacy, Qatar University, PO Box 2713, Doha, Qatar.

Email: elewahazem@gmail.com



Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (<http://www.creativecommons.org/licenses/by-nc/4.0/>) which permits non-commercial use,

reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<https://us.sagepub.com/en-us/nam/open-access-at-sage>).

protein binding (eg, cholestyramine); synergistic pharmacodynamic effect leading to increased risk of bleeding (eg, antiplatelets); eradication of vitamin K producing intestinal flora (eg, antibiotics and antifungals). In addition to drug interactions, most dietary products rich in vitamin K and those altering CYP enzyme activity can affect warfarin action.³ Whether the warfarin interaction is drug–drug or drug–food, it may lead to serious adverse effects—where inhibition of warfarin effect can lead to treatment failure and recurrence of thromboembolic events, while potentiation of warfarin effect can lead to increased risk of bleeding that may range from minor to life-threatening bleeding and death.^{4–6} Although direct oral anticoagulants (DOACs) such as dabigatran, rivaroxaban, apixaban, edoxaban, and betrixaban offer advantages over warfarin, their use is still limited due to the increase in gastrointestinal side effects, contraindication in patients with major renal dysfunction, and lack of superiority when compared to patients with well-managed warfarin therapy.^{7–10} Lastly, the cost of DOACs compared to warfarin may be prohibitive for many patients.¹¹ This has led warfarin to remain as the most widely prescribed oral anticoagulant in many countries despite challenges with its management.^{12–17} Variety of models are used in warfarin management including patient self-management, specialized anticoagulation clinics, and pharmacist-managed anticoagulation clinics.¹⁸ Pharmacist-managed anticoagulation clinic represents a model that provides patients with more consistent management, closer monitoring, more education, and awareness especially in regard to interacting drugs and food which can ultimately alter warfarin efficacy and safety.^{18–21}

One strategy to manage patients on warfarin starting an interacting drug is to increase the frequency of monitoring. Another strategy is to adjust warfarin dose around the time patient is started on an interacting medication, which is known as “preemptive warfarin dose adjustment.” Most studies evaluating these strategies focused on warfarin interactions with anti-infective agents. In this study, we explore the effect of warfarin interactions with wide variety of medications on the quality of anticoagulation management in a pharmacist-managed anticoagulation clinic in Al Wakra hospital, Hamad Medical Corporation (HMC). The main objective is to compare preemptive to nonpreemptive strategy and their impact on the quality of anticoagulation management.

Aim of Study

To evaluate the different strategies used by the clinical pharmacists working in the anticoagulation clinic and to compare the incidence of supratherapeutic INR in preemptive dose adjustment group versus the control group.

Ethics Approval

The institute of research board at HMC approved the study protocol.

Methods

Design and Setting

The study design was a retrospective cohort study aiming to compare preemptive versus nonpreemptive strategies in managing drug interactions with warfarin. A retrospective chart review of all eligible patients enrolled at Al-Wakra pharmacist-managed anticoagulation clinic was performed. All INR testing in clinic is performed with point-of-care (POC) instruments. Per clinic policy, all INR values greater than 5 obtained from POC instruments were verified with central laboratory assessment. A biweekly calibration is performed for the clinic’s POC instrument using plasma calibration sets. In addition to the clinic paper-based flow sheet, all visits are documented on electronic medical records (Cerner).

Data Collection and Study Patients

The research subjects included eligible patients managed between the period of May 2013 to May 2017. A data abstraction form was developed in order to collect patients’ data from HMC computer and paper-based database. The following information was extracted from each eligible record: (1) patient demographics and baseline characteristics including age, gender, indication for anticoagulation, duration of anticoagulation, drug interacting with warfarin, degree of interaction, and INR goal; (2) INR data at baseline (4 weeks prior) and after the onset/offset of drug interaction.

Patients were eligible for inclusion if they have been followed at the pharmacist-based anticoagulation clinic at Al-Wakra and there was an initiation/discontinuation of a drug interacting with warfarin. Patients were excluded if they were less than 18 years of age or if they received anticoagulants other than warfarin. Anticoagulation clinical and hospital records were used for screening eligible patients.

Assessment of Outcomes

The primary outcome was to compare the impact of preemptive versus nonpreemptive strategies on the incidence of out-of-target INR (out-of-target INR was defined as INR above or below target range by ± 0.2) as well as the incidence of extreme out-of-range INR values, as defined by an INR ≤ 1.5 or ≥ 4.5 (definition previously used by Schulman et al).²²

Secondary outcomes included comparison of the overall frequency of INR monitoring, incidence of out-of-target INR and extreme out-of-range INR prior and during the interaction period. Change in frequency of INR monitoring in the preemptive versus nonpreemptive strategies was also compared. We also included a subgroup analysis of the primary outcomes based on the level of drug interaction. Levels of drug interactions were identified using LexiComp definitions. LexiComp interactions module was used to analyze the interactions.

Table 1. Interacting Medications and Number of Patients Affected.

Interacting Medication	Number of Patients
Penicillin	11
Other medications ^a	8
Metronidazole	7
Quinolones	5
Cephalosporins	5
Carbimazole	4
Cotrimoxazole	3
Levothyroxine	2
Omega 3	2
Celecoxib	2
Rifampicin	2
Fluconazole	2

^aOther medications = amiodarone, azithromycin, charcoal, celecoxib, diclofenac, digoxin, lansoprazole, ranitidine, toseamide.

Statistical Analysis and Sample Size

Both descriptive and inferential statistical analyses were applied for the collected data using IBM Statistical Package for Social Sciences (IBM SPSS version 25 software). Categorical variables were expressed as frequencies and percentages while continuous variables were expressed either as mean \pm standard deviation or median (interquartile range [IQR], for data that were not normally distributed). *t* test or Mann-Whitney *U* test (if data were not normally distributed) was used to compare continuous data. For paired continuous data, paired-*t* test or Wilcoxon signed rank test (if data were not normally distributed) was used. For categorical variables, either χ^2 or McNemar (for paired variables) tests were used. Statistically significant results were determined at a *P* value of $<.05$. All patients who met inclusion/exclusion criteria were included in the analysis.

Results

Over the period of 4 years (2013-2017), 340 patients were evaluated and 58 warfarin–drug interaction encounters were identified. Mean age of the patients was (57.7 ± 13.7) and 50% of them were females. Atrial fibrillation/flutter stroke prevention and treatment of venous thromboembolism were the 2 main warfarin indications (43.1% and 39.7%, respectively). Majority of the patients had an INR goal of 2 to 3 (84.5%). Interacting medications and the number of patients affected by each agent are mentioned in Table 1. Initiation of an interacting drug was the main cause of interaction (84.5%) while the remaining interactions (15.5%) were due to discontinuation of an interacting drug. Most of the drug interactions were either grade C (58.6%) or grade D (39.7%). Preemptive dose adjustment was used in 17 cases (29.3%). There were no statistical differences between preemptive and control groups in any of the demographic or baseline characteristics (Table 2). A list of all interacting drugs in our cohort and their frequency are listed in Table 1.

As expected, the whole cohort's overall frequency of INR monitoring after onset/discontinuation of interacting

medication increased compared to baseline (7 [9] vs 21 [16] days, $P < .001$). Due to the effect of the interaction on INR stability, overall incidence of out-of-target INR was statistically higher after interaction compared to baseline (32 [59.3%] vs 13 [24%], $P = .001$). Similarly, incidence of extreme out-of-range INR was also found to be higher after interaction compared to baseline but did not reach statistical significance (13 [23.6%] vs 6 [10.9%], $P = .143$; Table 3).

When we compared the change in the frequency of INR monitoring in the preemptive arm to the control arm, there was no statistical difference between both groups (-7.5 [27] vs -8.5 [70], $P = .92$; Table 4). However, incidence of out-of-target INR was statistically lower in the preemptive arm compared to the control group (41.2% [7/17] vs 69.2% [27/39], $P = .048$; Figure 1) indicating improved INR control with the preemptive strategy. Incidence of extreme out-of-range INR was numerically lower in the preemptive arm compared to the control but did not reach statistical significance (11.8% [2/17] vs 29.3% [12/41], $P = .139$).

In a subgroup analysis in patients with grade C interactions, the incidence of out-of-target INR (more than 0.2 from target) was significantly lower in preemptive dose adjustment group compared to the control group (22.2% [2/9] vs 75% [18/24], P value = .009). Moreover, patients with grade D interactions had numerically lower incidence of out-of-target INR in preemptive dose adjustment compared to control group but it did not reach statistical significance as shown in Table 5. Another subgroup analysis of extreme out of range INR ($1.5 \leq$ or ≥ 4.5) in preemptive dose adjustment group compared to the control group stratified by the grade of drug interaction with warfarin showed a lower incidence in patients with preemptive dose adjustment compared to control group in drug but it did not reach statistical significance as shown in Table 5.

Discussion

In this research work, we observed an improved INR control with the preemptive strategy that was evidenced by the decreased incidence of the out-of-target INR visits. Extreme out-of-range INR was also numerically lower compared to the nonpreemptive strategy but did not reach statistical significance. Benefit of the use of preemptive warfarin dose adjustment has been studied by others, however, results were conflicting.²³⁻²⁷ Three of these studies were retrospective observational studies that focused on preemptive dose reduction of warfarin in patients initiating metronidazole,^{23,25} sulfamethoxazole-trimethoprim,^{23,24} and levofloxacin.²⁴ While 2 other studies were randomized controlled trials (RCTs) by Dowd and colleagues and they compared preemptive warfarin dose reduction to reactive warfarin dose adjustment in patients receiving prednisone²⁶ and in patients receiving doxycycline.²⁷ The 3 observational studies indicated that patients with preemptive strategy were more likely to maintain therapeutic INR and not to have suprathreshold INR compared to the control group. These results were more pronounced in patients on metronidazole and sulfamethoxazole-trimethoprim than in

Table 2. Baseline Characteristics of Patients.

Characteristics ^a	Preemptive Adjustment Group, n = 17	Control Group, n = 41	P Value	Overall, n = 58
Age (years), mean \pm SD	53.9 \pm 13.9	59.3 \pm 13.5	.17	57.7 \pm 13.7
Female, n (%)	11 (64.7%)	18 (43.9%)	.15	29 (50%)
Indication			.32	
Atrial fibrillation/flutter	5 (29.4%)	20 (48.8%)		25 (43.1%)
Treatment of VTE	7 (41.2%)	16 (39%)		23 (39.7%)
Valve replacement	3 (17.6%)	3 (7.3%)		6 (10.3%)
Other	2 (11.8%)	2 (4.9%)		4 (6.9%)
Goal INR, n (%)			.69	
2.0-3.0	14 (82.4%)	35 (85.4%)		49 (84.5%)
2.5-3.5	3 (17.6%)	4 (9.8%)		7 (12.1%)
Other	0 (0%)	2 (4.9%)		2 (3.4%)
INR before interaction, mean \pm SD	2.3 \pm 0.6	2.4 \pm 0.8	.65	2.4 \pm 0.7
Weekly warfarin dose before interaction (mg), mean \pm SD	44.3 \pm 49.3	37.3 \pm 21.8	.58	39.3 \pm 32
Cause of interaction, n (%)			.43	
Initiating an interacting drug	13 (76.5%)	36 (87.8%)		49 (84.5%)
Discontinuing an interacting drug	4 (23.5%)	5 (12.2%)		9 (15.5%)
Categories of drug interactions, n (%)			.69	
B	0 (0%)	1 (2.4%)		1 (1.7%)
C	9 (52.9%)	25 (61%)		34 (58.6%)
D	8 (47.1%)	15 (36.6%)		23 (39.7%)

Abbreviations: INR, international normalized ratio; IQR, interquartile range; VTE, venous thromboembolism; SD, standard deviation.

^aBaseline characteristics are presented based on number of encounters. Categorical variables were compared using χ^2 or Fischer exact test, as appropriate. Age, dose, and INR were compared using independent t test and follow-up intervals were compared using Mann-Whitney U test.

Table 3. Effect of Drug Interactions on the INR Monitoring Frequency and Quality of Anticoagulation Management.^a

	After Interaction	Baseline	P Value
INR monitoring interval (days), median (IQR)	7 (9)	21 (16)	$P < .001$
Incidence of out-of-target INR, n (%)	32 (59.3%)	13 (24%)	$P = .001$
Incidence of extreme out-of-range INR, n (%)	13 (23.6%)	6 (10.9%)	$P = .143$

Abbreviations: INR, international normalized ratio; IQR, interquartile range.

^aInternational normalized ratio monitoring intervals were compared using Wilcoxon signed ranks test while out-of-target INR values and extreme out-of-range INR values were compared using McNemar test. International normalized ratio monitoring interval, out-of-target INR, and extreme out-of-range INR were compared in 48, 54, and 55 cases, respectively. Patients with missing values were excluded from these analyses.

patients on levofloxacin.²³⁻²⁵ On the other hand, both RCTs on warfarin–prednisone and warfarin–doxycycline interactions, found more control patients with INR of more than 1 point over the goal upper limit compared to the intervention group but these results did not reach statistical significance.^{26,27} There was also a statistical significance increase in the incidence of subtherapeutic INRs in the preemptive group. Controversy in these studies' results is likely justified by the differences in the study design, extent of dose reduction made in the preemptive arm, measured outcomes, and the studied drug interaction. For example, medications such as

Table 4. Effect of Preemptive Dose Adjustment of Warfarin on the INR Monitoring Frequency.

	Preemptive Adjustment Group, n = 14	Control Group, n = 34	P Value ^a
INR monitoring interval before interaction (days), median (IQR)	14 (14)	21 (16)	.13
Difference in monitoring interval (days), median (IQR) (after–before)	–7.5 (27)	–8.5 (70)	.92

Abbreviations: INR, international normalized ratio; IQR, interquartile range.

^aMonitoring intervals were compared using Mann-Whitney U test.

sulfamethoxazole-trimethoprim and metronidazole are well known to have higher level of interaction with warfarin and to induce more consistent elevation in INR.^{28,29} This justifies the positive impact of preemptive strategy seen in the research work studying the warfarin interaction with these drugs. In our study, all different medications interacting with warfarin were included. About 20% of these observed interactions, however, were with metronidazole and sulfamethoxazole-trimethoprim (Table 1).

Based on our subgroup analysis that stratified interacting medications according to degree of interaction, a significantly lower out of range INR was seen in preemptive dose adjustment versus control in category C interaction. This was the only statistically significant result in this subgroup analysis. Other results showed some trend of less extreme out of range




Figure 1. Effect of preemptive dose adjustment strategy on the percentage of out-of-target INR values. Out-of-target INR was defined as INR above or below target range by more than 0.2. * χ^2 test was used to compare the 2 strategies. INR indicates international normalized ratio.

Table 5. Subgroup Analyses of Preemptive Dose Adjustment Compared to Control Group Comparisons Based on Degree of Interaction.

Comparison	Grade of Interaction	Preemptive Dose Adjustment	Control Group	P Value
The incidence of out-of-target INR (more than 0.2 from target), (%)	C	2/9 (22.2%)	18/24 (75%)	.009
	D	5/8 (62.5%)	8/15 (57.1%)	.584
The incidence of extreme out of range INR ($1.5 \leq$ or ≥ 4.5), (%)	C	0/9 (0%)	7/24 (28%)	.089
	D	2/8 (25%)	4/15 (26.7%)	.666
Frequency of INR monitoring (number of days between visits), median (IQR)	C	5 (2.5)	10 (8.5)	.05
	D	6 (11)	9 (11)	.36

Abbreviations: INR, international normalized ratio; IQR, interquartile range.

INR in the preemptive dose adjustment group although these results were not statistically significant (Table 5).

Our study also indicates that warfarin drug interactions increase the need for frequent INR visits due to instability in the INR. However, there was still an increased incidence in the out-of-range INR visits postinteraction compared to baseline. This result is in alignment with previous report by Raebel et al where warfarin monitoring in patients receiving antimicrobial therapy was evaluated.³⁰ The study found that 77% of the patients were seen within 14 days of the initiation of the interacting medication.

Our study must be taken in context of several limitations. First, the study was observational in nature and may have been

exposed to selection bias that could impact its internal validity. Additionally, our study sample may have been inadequate since it was not powered. Instead, we relied on capturing all drug interactions that occurred at the clinic since it was launched. Further, percentage dose reduction or increase was not always consistent since it was a clinical decision based on the interacting medication and the patient condition and was left at the discretion of the pharmacist running the clinic.

Despite these limitations, our study is considered unique since it is one of few studies that looked at wide variety of medications interacting with warfarin and was not specific to 1 or 2 medications. There was also a limited attrition and information bias since we had good record of patients' INR at baseline and after the interaction.

Conclusion

Drug interactions with warfarin are associated with impaired INR control that requires more frequent follow-up visits to adjust warfarin dose. Preemptive strategy is shown in our study to decrease incidence of the out-of-target INR visits, although patients remained in need for close monitoring. Future randomized prospective studies are warranted to confirm these findings.

Authors' Note

This work has been presented at ACCP Fall meeting in 2017: Fahmi A, Mohamed A, Elewa H, and Saad M. Management of warfarin drug interactions in a pharmacist managed anticoagulation clinic: evaluation of frequency of INR monitoring and preemptive dose adjustment. ACCP fall conference, October 7-10, 2017, Phoenix, Arizona.


Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work is supported by Medical Research Center, Hamad Medical Corporation. RP#17226/17.

ORCID iD

Hazem Elewa  <https://orcid.org/0000-0003-1594-1199>

References

1. Nutescu EA, Spinler SA, Dager WE, Bussey HI. Transitioning from traditional to novel anticoagulants: the impact of oral direct thrombin inhibitors on anticoagulation management. *Pharmacotherapy*. 2004;24(10 pt 2):199S-202S.
2. Horton JD, Bushwick BM. Warfarin therapy: evolving strategies in anticoagulation. *Am Fam Physician*. 1999;59(3):635-646.
3. du Breuil AL, Umland EM. Outpatient management of anticoagulation therapy. *Am Fam Physician*. 2007;75(7):1031-1042.
4. Almog S, Martinowitz U, Halkin H, Bank HZ, Farfel Z. Complex interaction of rifampin and warfarin. *South Med J*. 1988;81(10):1304-1306.

5. Fahmi A, Abdelsamad O, Elewa H. Rifampin-warfarin interaction in a mitral valve replacement patient receiving rifampin for infective endocarditis: a case report. *SpringerPlus*. 2016;5:8.
6. Nutescu EA, Shapiro NL, Ibrahim S, West P. Warfarin and its interactions with foods, herbs and other dietary supplements. *Expert Opin Drug Saf*. 2006;5(3):433-451. doi:10.1517/14740338.5.3.433.
7. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med*. 2009;361(12):1139-1151. doi:10.1056/NEJMoa0905561.
8. Spyropoulos AC, Goldenberg NA, Kessler CM, et al. Comparative effectiveness and safety of the novel oral anticoagulants: do the pivotal clinical trials point to a new paradigm? *J Thromb Haemost*. 2012;10(12):2621-2624. doi:10.1111/jth.12005.
9. Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. *Lancet*. 2010;376(9745):975-983. doi:10.1016/S0140-6736(10)61194-4.
10. Pragst I, Zeitler SH, Doerr B, et al. Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model. *J Thromb Haemost*. 2012;10(9):1841-1848. doi:10.1111/j.1538-7836.2012.04859.x.
11. Huang C, Siu M, Vu L, Wong S, Shin J. Factors influencing doctors' selection of dabigatran in non-valvular atrial fibrillation. *J Eval Clin Pract*. 2012;19(5):938-943. doi:10.1111/j.1365-2753.2012.01886.x.
12. Avci BK, Vatan B, Tok OO, et al. The trends in utilizing non-vitamin K antagonist oral anticoagulants in patients with nonvalvular atrial fibrillation a real-life experience. *Clin Appl Thromb Hemost*. 2016;22(8):785-791. doi:10.1177/1076029615581365.
13. Hanemaaijer S, Sodihardjo F, Horikx A, et al. Trends in antithrombotic drug use and adherence to non-vitamin K oral anticoagulants in the Netherlands. *Int J Clin Pharm*. 2015;37(6):1128-1135.
14. Xu Y, Holbrook AM, Simpson CS, Dowlatsahi D, Johnson AP. Prescribing patterns of novel oral anticoagulants following regulatory approval for atrial fibrillation in Ontario, Canada: a population-based descriptive analysis. *CMAJ Open*. 2013;1(3):E115-E119.
15. Kirley K, Qato DM, Kornfield R, Stafford RS, Alexander GC. National trends in oral anticoagulant use in the United States, 2007 to 2011. *Circ Cardiovasc Qual Outcomes*. 2012;5(5):615-621.
16. Sørensen R, Gislason G, Torp-Pedersen C, et al. Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. *BMJ open*. 2013;3(5):e002758.
17. Barnes GD, Lucas E, Alexander GC, Goldberger ZD. National trends in ambulatory oral anticoagulant use. *Am J Med*. 2015;128(12):1300-1305. e2.
18. Nutescu EA. Anticoagulation management services: entering a new era. *Pharmacotherapy*. 2010;30(4):327-329.
19. Garton L, Crosby JF. A retrospective assessment comparing pharmacist-managed anticoagulation clinic with physician management using international normalized ratio stability. *J Thromb Thrombolysis*. 2011;32(4):426-430. doi:10.1007/s11239-011-0612-7.
20. Young S, Bishop L, Twells L, Dillon C, Hawboldt J, O'Shea P. Comparison of pharmacist managed anticoagulation with usual medical care in a family medicine clinic. *BMC Fam Pract*. 2011;12:88. doi:10.1186/1471-2296-12-88. 1471-2296-12-88.
21. Elewa H, Jalali F, Khudair N, Hassaballah N, Abdelsamad O, Mohammed S. Evaluation of pharmacist-based compared to doctor-based anticoagulation management in Qatar. *J Eval Clinical Practice*. 2016;22(3):433-438. doi:10.1111/jep.12504.
22. Schulman S, Parpia S, Stewart C, Rudd-Scott L, Julian JA, Levine M. Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial. *Ann Intern Med*. 2011;155(10):653-659. W201-W203. doi:10.7326/0003-4819-155-10-201111150-00003.
23. Powers A, Loesch EB, Weiland A, Fioravanti N, Lucius D. Preemptive warfarin dose reduction after initiation of sulfamethoxazole-trimethoprim or metronidazole. *J Thromb Thrombolysis*. 2017;44(1):88-93.
24. Ahmed A, Stephens JC, Kaus CA, Fay WP. Impact of preemptive warfarin dose reduction on anticoagulation after initiation of trimethoprim-sulfamethoxazole or levofloxacin. *J Thromb Thrombolysis*. 2008;26(1):44-48.
25. Holt RK, Anderson EA, Cantrell MA, Shaw RF, Egge JA. Preemptive dose reduction of warfarin in patients initiating metronidazole. *Drug Metabol Drug Interact*. 2010;25(1-4):35-39.
26. Dowd MB, Vavra KA, Witt DM, Delate T, Martinez K. Empiric warfarin dose adjustment with prednisone therapy: a randomized, controlled trial. *J Thromb Thrombolysis*. 2011;31(4):472-477.
27. Dowd MB, Kippes KA, Witt DM, Delate T, Martinez K. A randomized controlled trial of empiric warfarin dose reduction with the initiation of doxycycline therapy. *Thromb Res*. 2012;130(2):152-156.
28. Hale SF, Lesar TS. Interaction of vitamin K antagonists and trimethoprim-sulfamethoxazole: ignore at your patient's risk. *Drug Metabol Drug Interact*. 2014;29(1):53-60.
29. Howard-Thompson A, Hurdle AC, Arnold LB, Finch CK, Sands C, Self TH. Intracerebral hemorrhage secondary to a warfarin-metronidazole interaction. *Am J Geriatr Pharmacother*. 2008;6(1):33-36. doi:10.1016/j.amjopharm.2008.03.003.
30. Raebel MA, Witt DM, Carroll NM, Magid DJ. Warfarin monitoring in ambulatory older individuals receiving antimicrobial therapy. *Pharmacotherapy*. 2005;25(8):1055-1061.